Earnings
Rocket Doctor AI Announces Strong Q1 Momentum Driven by U.S. Expansion, New Payer Contracts and Platform Growth
AI Virtual Care Platform Accelerates U.S. Visits and Secures Cash Runway, But Margin Compression and Going Concern Doubts Loom

Executive Summary
- Rocket Doctor AI reported Q1 2026 financial results showing continued organic revenue growth to $737.1K CAD (5.7% QoQ) and a net loss of $4.64M CAD ($0.05/share).
- U.S. patient visits surged 283% sequentially to 678 in Q1, with April 2026 monthly visits reaching ~1,200 (69% MoM growth).
- The company expanded its U.S. in-network reach to over 21 million insured members across California, New York, and Maryland.
- Gross margin compressed to 75% from 84% in Q4 2025 and 88% in Q3 2025, attributed to revenue mix shifts post-acquisition and higher variable costs.
- Strategic milestones included the completed acquisition of Alea Health Holdings Ltd., a $5.2M upsized private placement financing, and ~$2.05M in warrant exercise proceeds.
- Cash and cash equivalents increased to $3.5M as of March 31, 2026, following the financing activities.
- Revenue recognition for U.S. operations remains on a cash basis due to IFRS 15 complexities with Medicare, Medicaid, and private insurance reimbursement timelines.
Material Impact
- The Q1 results validate the company's stated U.S. expansion strategy, with visit volumes accelerating significantly. However, the cash-basis revenue recognition policy means reported revenue is artificially lagging actual service delivery, masking the true monetization pace of the 21M-member network.
- Gross margin deterioration to 75% is a notable negative development, likely driven by the lower-margin Alea Health acquisition and increased direct costs associated with scaling U.S. operations.
- The $7.25M total capital raised in Q1 ($5.2M private placement + $2.05M warrants) provides a short-term cash runway but does not resolve the underlying profitability issue. The company continues to burn cash at an accelerated rate ($4.64M net loss in Q1).
- The news is consistent with prior announcements regarding U.S. payer contract signings and operational scaling. It does not introduce unexpected catalysts or structural changes to the business model.
AIDR · Price
Company Overview
- Rocket Doctor AI operates an AI-powered digital health platform delivering virtual primary care, urgent care, mental health, and chronic disease management.
- Flagship technology includes the Global Library of Medicine (GLM), a clinically validated AI decision engine, and the Rocket Doctor marketplace connecting patients with board-certified physicians.
- The company recently acquired Rocket Doctor Inc. (April 2025) and Alea Health Holdings Ltd. (Jan 2026), expanding its service portfolio to include conversational AI mental health tools and a foothold in the Middle East market.
- Strategic focus is on scaling physician-led virtual care across North America, with heavy emphasis on U.S. payer network integration and B2B white-labeling opportunities.
More from Rocket Doctor AI Inc.
Jun 30, 2026 · 08:00